– USA, PA – Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus therapeutic solutions company, today announced that Andrew Cheng, M.D., Ph.D., has been appointed to the Arbutus Board of Directors effective August 17, 2019.
“We are pleased to welcome Dr. Cheng to the Arbutus Board,” said Dr. Frank Torti, Chairman of the Arbutus Board of Directors. “I am confident Dr. Cheng, who brings a wealth of clinical development expertise in antivirals to our Board, will be of great value to our efforts to deliver a cure for people with chronic HBV.”
William Collier, President and CEO of Arbutus, added, “Dr. Cheng has extensive experience in the pharmaceutical industry and has achieved numerous successful clinical development outcomes for several antiviral compounds. We look forward to his guidance as we prepare for multiple clinical readouts from our HBV pipeline in the 2019/2020 timeframe.”
About Dr. Cheng
Dr. Cheng is currently President and Chief Executive Officer of Akero Therapeutics (Nasdaq: AKRO), a biotechnology company focused on the development of transformational treatments for non-alcoholic steatohepatitis and other serious metabolic diseases.
Previously, Dr. Cheng spent nearly two decades at Gilead Sciences, Inc., where he most recently served as Chief Medical Officer and Executive Vice President. Dr. Cheng joined Gilead Sciences in 1999 and was responsible for leading the clinical development for numerous HIV/AIDS programs. During his tenure at Gilead, he also led the clinical development operations for several other therapeutic areas including oncology, inflammatory, respiratory and cardiovascular indications.
“I look forward to working with the Arbutus Board of Directors and Executive Team as the Company looks to advance its two lead compounds through Phase 1a/1b clinical trials,” said Dr. Cheng. “I believe that Arbutus’ diverse pipeline, focused solely on HBV, holds great promise for people suffering from HBV.”
Dr. Cheng received a B.A. from the Johns Hopkins University and an M.D. and Ph.D. from Columbia University College of Physicians and Surgeons. He is board-certified in Internal Medicine.
About Arbutus
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which has the potential to improve upon the standard of care and contribute to a curative combination regimen.
For more information: http://www.arbutusbio.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
